FLGR242 Research Overview (also known as Recombinant Follistatin FLGR242, Follistatin-Albumin Construct, Extended Half-Life Follistatin)
A recombinant follistatin-albumin fusion protein engineered to selectively inhibit myostatin and related TGF-β superfamily ligands while extending circulation via albumin binding technology. Research focuses on skeletal muscle hypertrophy, myostatin pathway modulation, and fibroblast-matrix biology. Remains strictly research-use only with no approved human clinical indications as of 2026.
What Is FLGR242?
FLGR242 is a recombinant follistatin-albumin fusion protein engineered to selectively inhibit myostatin (GDF-8) and related TGF-β superfamily ligands, while minimizing activin binding and extending circulation time via albumin fusion technology. Unlike native Follistatin-344 — which binds both myostatin and activin, raising endocrine safety concerns — FLGR242 is a fragmented, modified construct designed to preserve high-affinity myostatin antagonism while eliminating or greatly reducing activin binding. The albumin-binding fusion segment dramatically extends circulatory half-life compared to native follistatin, enabling weekly or biweekly dosing. As of 2026, FLGR242 remains strictly research-use only (RUO) with no regulatory approvals and no formal Phase II/III human trials.
Key Benefits
- Selective myostatin antagonism via ligand-trap mechanism — increases satellite-cell activation, protein synthesis, and fiber hypertrophy in preclinical models
- Designed to spare activin binding, potentially reducing off-target endocrine and gonadal effects compared to native FST-344
- Extended circulatory half-life through albumin-binding fusion, enabling once-weekly or biweekly dosing rather than daily injections
- Dual research tracks: primary muscle/hypertrophy biology and a secondary fibroblast-matrix signaling track for extracellular matrix and tissue remodeling studies
- Conceptualized as a muscle-preserving adjunct in GLP-1-driven weight loss contexts to counteract lean mass reduction
Mechanism of Action
FLGR242 functions as a ligand trap: it binds myostatin and other ActRIIB ligands, preventing receptor interaction and lifting the inhibitory "brake" on muscle satellite-cell activation, fiber hypertrophy, and metabolic signaling. Downstream effects include suppression of Smad2/3 phosphorylation in muscle and metabolic tissues, modulation of TGF-β pathway balance affecting fibrosis and tissue remodeling, and reduced ActRIIB receptor activity. The albumin-binding peptide linker allows FLGR242 to bind circulating serum albumin, substantially extending its functional half-life to an estimated 5–15 days — a design adapted from albumin-fusion and Fc-fusion biologics. A separate research framing characterizes FLGR242 as a sequence-defined peptide analog modeling fibroblast-regulatory motifs involved in extracellular matrix assembly, representing a non-muscle research track distinct from the myostatin-inhibition application.
Research Indications
Skeletal Muscle & Hypertrophy
Myostatin inhibition drives increased lean mass, improved muscle cross-sectional area, and potential protection against sarcopenia or cachexia. Preclinical models show enhanced satellite-cell activation and protein synthesis. Integrative clinicians discuss improved recovery and strength accumulation over weeks, though human data for FLGR242 specifically remain anecdotal.
Metabolic & Body Composition
Myostatin-pathway modulation is associated with changes in fat-muscle partitioning, potential browning of white adipose tissue via improved mitochondrial biogenesis, and preliminary interest in hepatic steatosis and glucose metabolism. FLGR242-specific metabolic data are extrapolated from broader follistatin and myostatin inhibitor research.
Immune & Inflammation Biology
A secondary research track frames FLGR242 as an immunoregulatory peptide modulating pro-inflammatory versus pro-resolution signaling. In-vitro work examines fibroblast-mediated extracellular matrix remodeling and assembly. Specific receptor-binding profiles in immune contexts remain under investigation.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Muscle Hypertrophy — Macro | 5 mg | Once every 2 weeks | SubQ |
| Muscle Hypertrophy — Weekly | 2.5–5 mg | Once weekly | SubQ |
| MicroFLGR — Exploratory Signaling | 100–300 mcg | Once daily | SubQ |
| MicroFLGR — Intensive (short cycles) | 300–500 mcg | Once daily | SubQ |
Timing
Macro protocols: once weekly or every 2 weeks, SubQ (abdomen, thigh, upper arm). Avoid intramuscular injection. Onset of binding and signaling occurs within hours to days; visible hypertrophy effects develop over weeks, not days. Peak functional influence typically occurs mid-cycle. Micro-protocols run 10–30 days; macro protocols run 8–12 weeks. Allow at least 4–8 weeks off between cycles — the extended half-life (estimated 5–15 days) means functional activity persists well after the last injection.
Peptide Interactions
Stacking myostatin-blockers may compound unknown risks of excessive pathway suppression. The combined effect on cardiac muscle, fibrosis, and tissue remodeling is not characterized.
FLGR242 is a modified FST-344 analog. Simultaneous use is redundant and may complicate safety profiling — binding profiles could interfere and raise total follistatin activity unpredictably.
Mechanistically distinct pathways; sometimes co-used in hypertrophy stacks. No pharmacokinetic interaction data are available. GH axis support may be complementary for body composition goals.
Some protocols conceptually pair FLGR242 with Klotho for combined muscle and regenerative effects. Evidence is speculative with no controlled human data.
FLGR242 is conceptualized as a muscle-preserving adjunct during GLP-1-driven weight loss to counteract lean mass reduction. No formal interaction or combination data exist.
Immune modulation overlap exists conceptually. Interaction risk is uncertain; each class has been studied separately with no published combination safety data.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
No formal human safety profile exists — all use reflects preclinical data, vendor documentation, and anecdotal community reports only
Long-term myostatin/TGF-β blockade may affect cardiac muscle integrity, tendon strength, fibrosis dynamics, and tumor biology based on the broader TGF-β literature
SubQ injection only (abdomen, thigh, upper arm) — vendors specifically advise against intramuscular administration
Injection-site reactions (redness, mild pain, bruising) and transient muscle "heaviness" reported anecdotally at higher doses
Avoid stacking multiple growth-promoting peptides at high doses without qualified medical supervision
Do Not Use If:
Known or suspected malignancy — follistatin influences tumor biology and angiogenesis in some cancer contexts
Significant cardiomyopathy or structural heart disease — TGF-β pathway plays a critical role in cardiac remodeling
Pregnancy or breastfeeding
Seek Medical Attention If:
Unexpected muscle cramping, weakness, or joint pain
Any cardiac or respiratory symptoms
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Always consult a licensed physician before and during use
Quality Indicators
Verified
Lyophilized powder appearance
Off-white to white lyophilized powder, consistent with high-purity recombinant protein constructs. Discoloration or visible debris may indicate degradation.
Verified
Clear solution on reconstitution
When reconstituted with bacteriostatic water, solution should be clear and colorless. Turbidity, cloudiness, or yellowing signals degradation or contamination.
Caution
Vial stability vs. in vivo half-life
The extended half-life refers to in vivo circulation time, not vial stability. Reconstituted solutions should be used within 28 days refrigerated per vendor guidance.
CAUTION — NOT RECOMMENDED
Cloudy or colored solution
Yellowing, cloudiness, or particulate matter indicates the protein has degraded or is contaminated — not suitable for research use.
Verified
CoA and third-party testing
High-quality vendors provide HPLC purity (greater than 99%), mass spectrometry identity confirmation, and ideally endotoxin and sterility testing — critical given the protein size and complexity.
Reported Research Timeline
01First week (reported in cited studies): subtle changes in recovery and possible mild fullness in trained muscles. No rapid transformation — signaling onset occurs over days, not hours.
02Weeks 2–4 (reported in cited studies): noticeable shifts in body composition tracking (DEXA, measurements) in some subjects; modest strength trends and improved recovery from high-volume training reported.
03Weeks 4–8 (reported in cited studies): cumulative hypertrophy in responders; clearer lean mass differences and possible modest fat reduction. Progress is strongest when combined with optimized hormones, nutrition, and training.
04Weeks 8–12 (reported in cited studies): plateau potential. Continued gains depend more on training stimulus than peptide alone. Protocols commonly recommend cycling off after this window.
05Post-cycle (4–8 weeks): Anecdotal reports suggest maintenance of a portion of gains, with gradual normalization of signaling as peptide clears. The long half-life means effects taper rather than stop abruptly.
Research Citations
Research Focus
Muscle Hypertrophy, Myostatin Inhibition, TGF-β Modulation, Body Composition
Verified Vendors Carrying FLGR242
Frequently Asked Questions
What should researchers watch for with FLGR242?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with FLGR242?
First week (reported in cited studies): subtle changes in recovery and possible mild fullness in trained muscles. No rapid transformation — signaling onset occurs over days, not hours.
How is FLGR242 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →